Study on the Correlation Between Nucleoside Levels and the Efficacy of PARP Inhibitor Maintenance Therapy in Patients with Epithelial Ovarian Cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400079806

Enrollment

Unknown

Registered

2024-01-12

Start date

2024-01-16

Completion date

Unknown

Last updated

2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

Case series:none

Eligibility

Sex/Gender

Female

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with epithelial ovarian cancer at our center from January 1, 2018, to April 30, 2023; possessing sufficient tissue samples for testing; who have been treated with PARP inhibitors and have complete medical records and follow-up data.

Exclusion criteria

Exclusion criteria: Patients without tissue samples available for testing; those with incomplete medical records.

Design outcomes

Primary

Measure	Time frame
Modified Nucleoside Content in Tumor Tissue DNA;Modified Nucleoside Content in Blood Cell DNA;	—

Countries

China

Contacts

Public ContactLan Chunyan

Sun Yat-sen University Cancer Center

lanchy@sysucc.org.cn+86 189 2880 6306

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026